Kim ES, Velcheti V, Mekhail T, Yun C, et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat Med 2022 Apr 14. pii: 10.1038/s41591-022-01754.
PMID: 35422531